Abstract. Many patients with head and neck cancers receive radiation therapy as part of their treatment which frequently causes considerable morbidity, including various degrees of permanent salivary gland dysfunction. Threedimensional treatment planning [3-DTP] and conformational dose delivery constitute a new therapeutic modality that conforms the high-dose radiation volume to the shape of the tumor volume while minimizing the dose to tissue that is not at risk of containing cancer. The treatment volumes for head and neck tumors as well as parotid glands can be well-defined on cross-sectional CT imaging techniques. The purpose of this investigation is to determine if 3-DTP and conformational dose-delivery could minimize radiation dose and salivary gland dysfunction to contralateral parotid glands in patients with head and neck cancers. Eleven patients with head and neck cancers who required bilateral radiation therapy were treated with 3-DTP. Unstimulated and stimulated bilateral parotid saliva was collected prior to radiotherapy, weekly during treatment, and 1, 3, 6, and 12 months after the completion of radiotherapy. Treated parotid glands received an average dose of 5745 cGy, while spared glands received only 1986 cGy (p < 0.0001). Unstimulated and stimulated parotid flow rates decreased dramatically in treated glands after the initiation of radiotherapy, remained at extremely low rates without any improvements, and were significantly lower at 1 year after radiotherapy compared with baseline. Conversely, parotid flow rates in spared glands underwent mild changes during radiotherapy and were approximately 50% of baseline values. The results of this study suggest that with the use of 3-DTP, contralateral parotid gland function can be partially preserved for at least 1 year in patients with head and neck cancers requiring bilateral radiation.
Introduction
In 1995, there were an estimated 28,150 newly reported cases of oral-pharyngeal cancer in the United States, resulting in over 8370 deaths from these cancers (Wingo et al., 1995) . Many of these patients receive radiation therapy as part of their treatment. The goal of radiation therapy is to eradicate the tumor without causing significant or permanent damage to the oral-pharyngeal tissues that are at low risk for cancer spread (Semba et al., 1994) . Currently, many of the radiation therapy techniques used in the treatment of head and neck cancer have serious side-effects detrimental to the oral cavity, including the loss of salivary gland function and a persistent complaint of a dry mouth (xerostomia) . Salivary secretions contain numerous proteins and electrolytes that provide dental remineralization, antimicrobial action, lubrication, buffering, and mucosal repair (Mandel, 1989) . Patients with radiation-induced salivary dysfunction suffer from oral discomfort and mucositis, difficultly in chewing and swallowing, taste changes, dental caries, oral microbial changes, chronic esophagitis, and a diminished quality of life (Parsons, 1994; Whelton, 1996) . Despite much research, there is still no effective treatment for radiation-induced salivary dysfunction (Greenspan, 1990) .
Parotid glands consist entirely of serous acini, submandibular and sublingual glands contain mucous and serous acini, and minor salivary glands contain predominantly mucous acini (Young and Van Lennep, 1979) . Serous acini are thought to be the most radiosensitive, followed by mucous cells and duct cells (Stephens et al., 1986) . Data from rhesus monkey salivary glands (Stephens et al., 1991) suggest that irradiated serous cells undergo interphase cell death by a process of active cellular self-destruction (apoptosis).
Previous studies of head and neck radiotherapy patients have shown that there is a dose-response relationship in parotid flow rates Mira et al., 1981; Marks et al., 1981) . For most head and neck cancers, radiation dosages delivered to tumor regions are greater than 4500 cGy (Parsons, 1994) . Doses of from 2100 to 4000 cGy have been shown to cause significant damage to 807 salivary glands (Mira et al., 1981 (Jones et al., 1996) . However, many patients with head and neck cancers require bilateral head and neck radiation due to extension of the cancer into the ipsilateral or bilateral lymph nodes. Usually these patients receive high-dose bilateral radiation, causing complete destruction of salivary gland function due to irradiation of both parotid glands (Franzen et al., 1992; Marks et al., 1981; Dreizen et al., 1977) .
The purpose of this investigation was to determine if 3-DTP and dose delivery could minimize radiation dose and salivary gland dysfunction to contralateral parotid glands in patients with head and neck cancers requiring bilateral radiation treatment without leading to an increase in locoregional failure (cancer recurrence). It was hypothesized that objective measurements of parotid salivary flow rates would be greater in spared glands compared with irradiated glands due to the use of 3-DTP and conformational dosedelivery techniques.
Materials and methods

Subjects
Entrance criteria for patients included an histologically confirmed invasive cancer of the head and neck region. Patients had to demonstrate a need for irradiation to both sides of the neck due to: (1) a central tumor; (2) a lateralized tumor and ipsilateral neck node metastases where the contralateral node involvement was high; or (3) the condition where the contralateral neck was clinically negative but contained microscopic disease which was surgically resected. A Southwestern Oncology Group (SWOG) performance status of 0-2 (Karnofsky > 40) was required for entrance into the study (Mor et al., 1984) . Patients who had previous surgery on the contralateral parotid were ineligible, but those who had cancer surgery on the ipsilateral gland prior to radiotherapy were eligible. A signed informed consent form was also required. The experimental protocol and the consent form were approved by the University of Michigan IRB.
3-D radiation treatment planning
All patients underwent immobilization and full 3-DTP through the University of Michigan Radiation-Oncology planning system (Hazuka et al., 1993) . The target volume included the primary tumor mass and lymph node areas which contained metastases along with adjacent areas that were at low risk for microscopic extension. Lymph node areas which were at risk for subclinical disease were defined and included in the target volume. For planning, the target volume was expanded by approximately 1 cm to account for uncertainties of the target location and set-up error. Both parotid glands were contoured into the planning system.
The goal of treatment planning was full exclusion of the contralateral parotid gland (in the case of a lateralized tumor) or the gland at the side of the neck least involved with the tumor (in the case of bilateral neck involvement) from the primary beam, with adequate volume coverage provided to the tumor area. If this was not possible, the treatment planning permitted the lowest dose possible to be administered to the contralateral gland or the side of the neck least involved. Frequently, the tail of the contralateral parotid gland was irradiated to provide complete coverage to contralateral subdigastric and jugular neck nodes. All patients were treated with continuous conventional fractionation, and received 1.8 Gy to 2.0 Gy fractions, 1 fraction per day, 5 fractions per week. All treatment was delivered with megavoltage energies by the linear acceleration or racetrack microtron.
Parotid salivary flow measurements Bilateral parotid saliva was collected prior to radiation treatment (baseline), weekly during treatment, and at 1, 3, 6, and 12 months after completion of radiotherapy. Subjects were instructed to refrain from eating, drinking, smoking, and oral hygiene for a minimum of 90 min prior to salivary collection. All patients were seen between 8 a.m. and Noon to control for circadian variations in salivary gland function (Dawes, 1974) . Unstimulated parotid saliva was collected from both parotid gland orifices (Stenson's duct) with the use of a CarlsonCrittenden cup as described previously (Baum, 1981;  Heft and Baum, 1984) . Salivary flow was stimulated by 2% citric acid swabbed onto the dorso-lateral surfaces of the tongue at 30-second intervals for 2 min for equilibration. This was followed by a two-minute collection period during which gustatory stimulation was maintained (Tylenda et al., 1988) . Following salivary collection, the volumes of all salivas were determined gravimetrically by means of an analytical balance, assuming a specific gravity of 1.0.
Saliva was collected by two investigators (JAS and REJ) who were calibrated for unstimulated and stimulated parotid salivary flow rates. Unstimulated and 2% citrate-stimulated parotid salivas were collected from eight unmedicated and healthy subjects by both investigators. Inter-examiner correlation coefficients were 0.924 for unstimulated parotid and 0.925 for stimulated parotid flow rates.
Statistical analysis
To control for inter-individual differences in flow rates (Ship et al., 1991) , we converted each subject's flow rates at each visit into the percentage of unstimulated or stimulated flow rate at baseline. Paired tests were used for comparisons between Parotid Sparing Radiation Therapyfor Cancer unstimulated and stimulated flow rates and percentages of baseline flow rates between untreated and spared glands for each collection period. Comparisons were also performed for unstimulated and stimulated parotid flow rates and the percentages of baseline flow rates between baseline and one-year postcompletion of radiation therapy for the treated and spared glands. A paired t test was used where mean values were assumed to have normal distribution, and a two-sample robust analysis was used where normality was not a plausible assumption (DuMouchel, 1987) . Direct comparisons (paired t tests) were used for the evaluation of differences in the amount of radiation delivered to the spared and treated glands. All data were analyzed with the RS/1 software package (BBN Software approximately 50% of baseline values at 1 yr after radiotherapy )f p < 0.05 was compared with baseline (p = 0.004). There were no significant differences in unstimulated salivary flow rates between treated and spared glands at baseline; however, at the completion of radiotherapy and at 1, 3, 6, and 12 months after the completion of radiotherapy, these differences were highly significant (Table  .ents with the exception of baseline (Table 4) . ates from the Salivary flow rates were also converted into percentages of r radiotherapy baseline flow rates to control for inter-individual differences. = 0.002), and
The results for percentages of baseline unstimulated (Fig. 3 ) es from treated and stimulated (Fig. 4) (Dreizen et al., 1977; Mira et al., 1981; Mossman et al., 1982) . Conversely, several studies demonstrated partial salivary function recovery which was dependent on radiation dose, field of treatment, and length of follow-up after the completion of therapy (Eneroth et al., 1972; Franzen et al., 1992 (> 6800 1986, 1991; Greenspan, 1990; Hazuka et al., 1993; cGy). This study and others suggest that if the amount of Parsons, 1994; Semba et al., 1994; Jones et al., 1996) . radiation to the contralateral parotid gland can be minimized, There is a dose-dependent relationship between the amount some salivary function can be spared.
of radiation delivered to oral tissues and the damage that
The one-year results of the present study demonstrate eventually occurs (Marks et Semba et al., 1994) . It has also been documented patients requiring bilateral radiation for head and neck that bilateral conventional radiotherapy causes greater oral cancers if 3-DTP and dose-delivery techniques are used. discomfort and increased complaints of xerostomia Through the use of 3-DTP, beam's-eye-view displays were compared with unilateral radiation therapy (Mira et al., used to design beam and blocking arrangements that 1981; Franzen et al., 1992) . excluded the contralateral parotid gland (Hazuka et al., 1993) .
Consequently, spared glands presence of some unstimulated treated glands compared wit function will allow for subsequent stimulation with mechanical, gustatory, and pharmacological agents (Greenspan, 1990; Johnson et al., 1993; LeVeque et al., 1993; Atkinson and Wu, 1994 There are some limitations to this study. First, this paper presents data on only 11 patients treated with bilateral 3-DTP up to 12 months after radiotherapy. Nevertheless, there are distinct and significant differences between spared and treated parotid glands. There are even slightly detectable trends of salivary gland recovery from spared glands with time. However, more patients are needed over a longer time period if we are to determine whether the trends observed are statistically significant in larger populations. Finally, subjective data on patients' xerostomia complaints are not included in this report. Responses to standardized xerostomia questions (Fox et al., 1987) Figure 4 . One-year data for percentages of baseline stimulated paroti and spared glands in 11 cancer patients receiving bilateral head and; significantly lower in treated glands compared with spared glands at may no longer be inevitable in patients with head and neck cancers who require bilateral radiation therapy. Parotid gland function can be partially preserved by 3-DTP, resulting in a decrease in radiation-induced dysfunction. Consequently, the use of gustatory, masticatory, and pharmacological saliva stimulants as well as aggressive oral hygiene techniques can be used to help preserve oral health.
